AGA Clinical Practice Update on Interaction between Oral Direct-Acting Antivirals (DAAs) for Chronic Hepatitis C Infection and Hepatocellular Carcinoma: Expert Review

Documenti analoghi

• AGA Clinical Practice Update on Interaction Between Oral Direct‐Acting Antivirals for Chronic Hepatitis C Infection and Hepatocellular Carcinoma: Expert Review
  di: Singal, Amit G., et al.
  Pubblicazione: (2020)
• Hepatitis C Disease Burden in the United States in the Era of Oral Direct-Acting Antivirals
  di: Chhatwal, Jagpreet, et al.
  Pubblicazione: (2016)
• Surveillance for Hepatocellular Carcinoma: Current Best Practice and Future Direction
  di: Kanwal, Fasiha, et al.
  Pubblicazione: (2019)
• Update on hepatitis C: Direct-acting antivirals
  di: Seifert, Leon L, et al.
  Pubblicazione: (2015)
• Recurrence of Hepatocellular Carcinoma in Hepatitis C Virus (HCV) Liver Transplant Recipients Treated with Pretransplant Direct-Acting Antiviral (DAA) Therapy
  di: Lim, Nicholas, et al.
  Pubblicazione: (2020)